In The News,
ADVI’s Lindsay Bealor Greenleaf talks to the Daily Caller about the court blocking Trump’s drug price disclosure requirement for TV ads
[el-text]
Written by Evie Fordham
***excerpt***
“The court ruling is an important check on administrative authority,” Lindsay Bealor Greenleaf, Director of Policy at ADVI Health, told the DCNF Tuesday. “Now it’s up to Congress to decide if they want to require list price disclosure for TV ads through legislation. Before pursuing this legislatively, Congress should carefully consider how list price disclosure in TV ads can mislead patients about a treatment’s affordability. List prices don’t account for the rebates and negotiated discounts — which totaled $166 billion in 2018 — that are provided to pharmacy benefits managers and other players in the supply chain, plus patients’ out-of-pocket costs vary from plan to plan.”
***end excerpt***
[/el-text]